Cytosolic cathepsin D levels in squamous carcinomas of the lung;Significado de la concentraciíon citosólica de catepsina D en el carcinoma escamoso de pulmón

Medicina Clinica

Volumn 120, Issue 3, 2003, Pages 81-84

  Ruibal Morell, Álvaro ^a   Núñez, Matilde Isabel ^a   del Rio, María del Carmen ^b   García Díez, Susana ^a   Rodríguez, Jesús ^c   Feliciano Álvarez de Linera, José ^c  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b UNIVERSIDAD ALFONSO X EL SABIO   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Cathepsin D; Cytosol; Lung; Squamous cancer

Indexed keywords

ASPARTIC PROTEINASE; CATHEPSIN D; CD44V ANTIGEN; CD44V5 ANTIGEN; CD44V6 ANTIGEN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; ONCOPROTEIN; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPROTEIN;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER STAGING; CELL CYCLE S PHASE; CELL FRACTIONATION; CELL SURFACE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSOL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; LUNG CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PLOIDY; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; COMPARATIVE STUDY; ENZYMOLOGY; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; CATHEPSIN D; CYTOSOL; GLYCOPROTEINS; HUMANS; IMMUNORADIOMETRIC ASSAY; LUNG NEOPLASMS; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 1242317545     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042641     Document Type: Article

References (47)

1. Tsukuba T, Okamoto K, Yasuda Y, Morikawa W, Nakanishi H, Yamamoto K. New functional aspects of cathepsin D and cathepsin E. Mol Cells 2000;10:601-11.
2. Vizoso F, Merino AM, Vázquez J, Lamela ML, Rodil A, García Muñiz JL. Significación biológica y clínica de los enzimas proteolíticas y sus inhibidores en los carcinomas humanos. Cir Esp 2000;68:471-85.
3. Coyne CP, Howell T, Baravick J, Baravick J, Baravick E, Willetto C, et al. Biochemical alteration of membrane-associated IL-6 RI (80KDA) in adherent macrophages and vascular endothelium. Mol Immunol 2001;38:347-57.
4. Coyne C, Baravick J, Howell T, Baravick E, Willetto C, Fenwick BW. Biochemical mechanisms that interact with membrane-associated IL-1 RII (60 Kda decoy) receptors in populations of adherent macrophages and vascular endothelium. Cell Signal 2001;13:765-76.
5. Bellelli A, Mattioni M, Rusconi V, Sezzi ML, Bellelli L. Inhibition of tumor growth, invasion and metastases in papain-immunized mice. Invasion Metastasis 1990;10:142-69.
6. Heylen N, Vincent LM, Devos V, Dubois V, Remacle C, Trouet A. Fibroblasts capture cathepsin D secreted by breast cancer cells: possible role in the regulation of the invasive process. Int J Oncol 2002;20:761-7.
7. Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002;235:10-26.
8. Tetu B, Brisson J, Wang CS, Lapointe H, Beaudry G, Blanchette C. Expression of cathepsin D, stromelysis-3 and urokinase by reactive stromal cells on breast carcinoma prognosis. Cancer 2001;92:2957-64.
9. Niu Y, Fu X, Lv A, Fan Y, Wang Y. Potential markers predicting distant metastasis in axillary node negative breast carcinoma. Int J Cancer 2002;98:754-60.
10. Aziz S, Pervez S, Kahan S, Kayani N, Rahbar M. Immunohistochemical cathepsin D expression in breast cancer: correlation with established pathological parameters and survival. Pathol Res Pract 2001;197:551-7.
11. Foekens A Look MP, Bolt-de Vries J, Meijer-Van Gelder ME, van Putten WL, Klijn JG. Cathepsin D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 1999;79:300-7.
12. Kashida H, Kawamata H, Ichikawa K, Morita K, Imura J, Fujimori T. Intracytolasmic localization of cathelosin D reflects the invasive potential of gastric carcinoma. J Gastroenterol 2001;36: 809-15.
13. Ikeguchi M, Sakatani T, Ueta T, Fukuda K, Oka S, Hisamitsu K, et al. Correlation between cathepsin D expression and p53 protein nuclear accumulation in oesophageal squamous cell carcinoma. J Clin Pathol 2002;55:121-6.
14. Zalweski B, Famulski W, Sulkowska M, Sobaniec-Lotowska M, Piotrowski Z, Kisielewski W, et al. CD44 expression in colorectal cancer. An immunohistochemical study including correlation with cathepsin D immunoreactivity and some tumour clinicopathological features. Folia Histochem Cytobiol 2001;39(Suppl 2):152-3.
15. Stroajn P, Budihna M, Smid L, Vrhovec I, Skrk J. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck. Anticancer Res 2000;20:3975-81.
16. Frohlich E, Schlagenhauff B, Mohrle M, Weber E, Klessen C, Rassner G. Activity, expression and transcription rate of the cathepsins B, D, H and L in cutaneous malignant melanoma. Cancer 2001;91:972-82.
17. Falcon O, Chirino R, León L, López Bonilla A, Torres S, Fernández L, et al. Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer. Br J Cancer 1999;79:570-6.
18. Saygili U, Koyuncuoglu M, Altunyurt S, Guclu S, Uslu T, Erten O. May cathepsin D immunoreactivity be used as a prognostic factor in endometrial carcinomas? A comparive immunohistochemical study. Gynecol Oncol 2001;83:20-4.
19. Suzumori N, Ozaki Y, Ogasawara M, Suzumori K. Increased concentrations of cathepsin D in peritoneal fluid from women with endometriosis. Mol Hum Reprod 2001;7:459-62.
20. Kasper M, Lackie P, Haase M, Schuh D, Muller M. Immunolocalization of cathepsin D in pneumocytes of normal human lung and in pulmonary fibrosis. Virchows Arch 1996;428:207-15.
21. Reid WA, Valler MJ, Kay J. Immunolocalization of cathepsin D in normal and neoplastic human tissues. J Clin Pathol 1996;39:1323-30.
22. Kuhn SH, De Koch MA, Gevers W. The diagnostic value of lysosomal enzyme patterns in bronchial aspirates of patients with suspected bronchial carcinoma. Chest 1978;74:150-6.
23. Sloman A, D'Amico F, Yousem SA. Immunohistochemical markers of prolonged survival in small cell carcinoma of the lung. An immunohistochemical study. Arch Pathol Lab Med 1996; 120:465-72.
24. Ruibal A, Núñez MI, del Río MC, Rodríguez J, Álvarez de Linera JF. Utilidad de la determinación del activador del plasminógeno tipo tisular (t-AP) citosólico en el adenocarcinoma de pulmón. Med Clin (Barc) 2002;119:1-3.
25. Ledakis P, Tester WT, Rosenberg N, Romero-Fischmann D, Daskai I, Lab TT. Cathepsin D, B and L in malignant human lung tissue. Clin Cancer Res 1996;2:561-8.
26. Uchiyama B, Saijo Y, Kumano N, Abe T, Fujimura S, Ohkuda K, et al. Expression of nucleolar protein p120 in human lung cancer: difference in histological types as a marker for proliferation. Clin Cancer Res 1997;3:1873-7.
27. Sikora J, Dworacki G, Trybus M, Atura-Gabryel H, Zeromski J. Correlation between DNA content, expression of Ki67 antigen of tumor cells and immunophenotype of lymphocytes from malignant pleural effisions. Tumor Biol 1998;19: 196-204.
28. Ishikuro A, Dosaka-Akita H, Kato M, Fujino M, Isobe H, Miyamoto H, et al. Ki-67 labeling indices in non-small cell lung cancer: comparison between image cytometry and flow cytometry. Cytometry 1997;39:186-91.
29. Nguyen VN, Mirejovsky P, Mirejovski T, Molineva L, Mandys V. Expression of cyclin D1, Ki67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. Acta Histochem 2000;102:323-38.
30. Visakorpi T, Holli K, Hakama M. High cell proliferation activty determined by DNA flow cytometry and prognosis in epidermoid lung carcinoma. Acta Oncol 1995;34 605-9.
31. Filderman AE, Silvestrini GA, Gatsonis C, Luthringer DJ, Honig J, Flynn SD. Prognostic significance of tumor proliferative fraction and DNA content in stage I non small cell lung cancer. Am Rev Respir Dis 1992;146:707-10.
32. Kawai T, Suzuki M, Kono S, Shinomiya N, Rokutanda M, Takagi K, et al. Proliferating cell nuclear antigen and Ki67 in lung carcinoma. Correlation with DNA flow cytometric analysis. Cancer 1994;74:2468-75.
33. Álvarez Riesgo JA, Sampedro A, Fernández R, Folgueras MV, Salas-Bustamante A, Cueto A. Cell proliferation activity and prognostic index in squamous cell lung carcinoma. Anal Cell Pathol 1998;16:233-42.
34. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA Jr. Epidernal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002;29:3-14.
35. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002;29;27-36.
36. Díez M, Maestro ML, Torres A, Hernando F, Ortega MD, García Asenjo JA, et al. El receptor del factor de crecimiento epidérmico en el carcinoma no microcítico de pulmón. Arch Bronconeumol 1994;30:282-6.
37. Pfeiffer P, Clausen PP, Andersen K, Rose C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systematically untreated non-small cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 1996;74:68-91.
38. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi H, Angeletti CA, et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement og hilar and meiastinal lymph nodes in the squamous subtype. Eur J Cancer 1995;31: 178-83.
39. Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993; 68:162-5.
40. Ohsaki T, Tanno S, Fujita Y, Toyoshima E, Fujiuchi S, Nishigaki Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000;7:603-7.
41. Cox G, Jones JL, O'Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000;6:2349-55.
42. Kolodziejski L, Niezabitowski A, Gasinska A. Clinical abd flow cytometric prognostic factores in surgically tretated squamous cell lung cancer. Lung Cancer 1997;16:173-82.
43. Reinmuth IN, Brandt B, Kunze WP, Junker K, Thomas M, Achatzy R, et al. Plody, expression of erb, erbB2, p53 and amplifiaction of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J 2000;16:991-6.
44. Penno MB, August JT, Baylin SB, Mabry M, Linnoila RI, Lee VS, et al. Expression of CD44 in human lung tumors. Cancer Res 1994;54:1381-7.
45. Teder P, Bergh J, Heldin P. Functional hyaluronan receptors are expressed on a squamous cell lung carcinoma cell line but not on other lung carcinoma cell lines. Cancer Res 1995;55: 3908-14.
46. Nguyen VN, Mirejovsky T, Melinova L, Mandys V. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma 2000; 47:400-8.
47. Pirinen R, Hirvikoski P, Bohm J, Krellokoski J, Moisio K, Viren M, et al. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma. Hum Pathol 2000;31:1088-95.